As Amgen's Prolia Goes, So Goes The Market: Reaction To AC Recs

FDA and the Reproductive Health Drugs Advisory Committee's focus on small imbalances in Amgen's trial data for Prolia (denosumab) sparked disparate reactions on the Street, with some analysts trimming their estimates and others holding tight